New GMP-grade Recombinant Human IL-15 is available, produced in our new GMP manufacturing facility. GMP IL-15 pairs with our GMP IL-7 for ex vivo expansion of CAR-T and TCR cell therapies.
Our New T Cell-Based Therapies eBook lays out some of the major biological and manufacturing challenges facing the industry today. It follows up with examples of how Bio-Techne products and services address these challenges at each stage of the process.
Our New FlowX™ Human NK Cell Killing Flow Cytometry Kit analyzes the capability of NK and NK-CAR cells to target and kill cells of interest. The assay is based on direct detection of LAMP proteins and does not require the use of radioactive labels.
Our New FlowX™ Human NK Cell Phenotyping Flow Cytometry Kit enables the single-step analysis of expanded human NK cells. It contains 6 fluorochrome-conjugated antibodies and 6 isotype controls, plus staining buffer.
Our new page, Transitioning to Animal-Free and GMP, walks you through how we help you advance your program to the clinic as easily as possible. The page includes data showing how you can expect equivalent bioactivity from our reagents regardless of the grade.
New GMP-grade Recombinant Human IL-10. This is the first commercially available GMP version of human IL-10, and we produce it in our new GMP manufacturing facility.
Bio-Techne and Akoya Biosciences announce their partnership to deliver an Automated Spatial Multiomics workflow with industry-leading speed and resolution. Bio-Techne's RNAScope™ technology combined with Akoya's PhenoCycler™-Fusion system will enable comprehensive spatial phenotyping of RNA and protein biomarkers.
Regulus Therapeutics Collaborates with Bio-Techne for Biomarker Development. Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to aid in their clinical trial patient testing. Learn More About Our Collaboration
Bio-Techne Announces ISO 13485:2016 Certification for the Woburn, MA Manufacturing Facility. The Woburn facility produces Cloudz™ Cell Activation Kits, a magnetic-free microsphere technology for the robust and reliable expansion of immune cells, including T cells and NK cells, representing a pivotal component of the cell and gene therapy workflow. Learn More About Our Manufacturing Certification
Bio-Techne Announces Grand Opening of our new, state-of-the-art GMP Manufacturing Facility in Saint Paul Minnesota. Learn About Our GMP Facility
B-MoGen Biotechnologies officially becomes part of R&D Systems. B-MoGen, a genome engineering services company, was acquired by Bio-Techne in 2019. Read About Our Gene Engineering Services
GMP ProDots™ Proteins are now available. These GMP cytokines are formulated as dissolvable spheres enclosed inside sterile, weldable bags for closed processing cytokine addition. View ProDots at R&D Systems
Cell and Gene Therapy Symposium: Streamlining Scale-Up and Scale-Out
Bio-Techne is hosting our next Cell and Gene Therapy Virtual Symposium. At our last event, we discussed “The Challenges of Analyzing ATMPs” and our speakers shared solutions to overcome these challenges. To create therapies that are accessible to all, it is key that manufacturing can be completed in a scalable and cost-effective manner. So, this time we shall be exploring the challenges and discussing possible solutions for streamlining the manufacturing process. Join us and be part of the discussion on how we can streamline, scale-up and scale-out!
Pioneering Solutions for Regenerative Medicine: From GMP Ancillary Material to Product Analysis
During this session we will discuss innovative solutions for regulatory-compliant raw materials and instrumentation across the ex vivo manufacturing workflow for stem cell and immune cell therapies.
Streamlining Cell Therapy IND Submission: Leveraging Raw Material Supplier Partnerships
Bringing a cell or gene therapy from discovery to the clinic cannot be done in isolation. Join Dr. Derek Hei from BlueRock Therapeutics and Dr. Dan Fowler from Rapa Therapeutics as they discuss how their partnerships with Bio-Techne are helping them build robust and scalable manufacturing platforms and facilitate their IND submissions.
Planning for Success: Emerging GMP-Grade Raw Materials & Technologies for Cell Therapy
Join our panel of industry leading CGT experts as they discuss planning for the successful development of new cell therapies using new raw materials and technologies. Topics include raw material optimization, best practices, risk assessment and challenges for new raw material, regulatory considerations, scale up and production, and more.
Tocris GMP Raw Materials for Cell Therapy: What, When, How
Listen to a discussion by our panel of experts, Jean Stanton (J&J), John Tomtishen (Novartis), Dr. Sadik Kassim (Mustang Bio), and Dr. Diane Wotta (Bio-Techne), around what GMP really means in the context of raw materials and ancillary reagents; the quality of raw materials required along the commercialization pathway; when to start using GMP materials; and the current regulatory landscape.
Analytical Solutions for Cell and Gene Therapy – Advancing your AAV and CAR T-cell development with Maurice and MFI by ProteinSimple
Cell and gene therapy is a rapidly advancing field that holds a lot of promise for treating a wide range of diseases. In this webinar we'll discuss how our Maurice and MFI 5200 systems can assist with the cell and gene therapy workflow.
Cell Analysis and Host Response
Cell and Gene Therapy Symposium: Challenges of Analyzing ATMPs
Bio-Techne looks forward to welcoming you to this exciting virtual event to discuss the latest topics within the cell & gene therapy community. The theme for this 2nd virtual symposium is a discussion around the “Challenges of analyzing ATMPs”. Join us to find out from leading scientists how they are pushing the boundaries of cell & gene therapy research.
Monitoring Host Immune Responses: Critical Factors for Accuracy, Reproducibility and Throughput.
Monitoring immune responses accurately is critical. From acute infections to cancer immunotherapy, the identity and level of secreted cytokines is needed to understand and control the immune system. This webinar will describe the assays used and the importance of obtaining accurate results.
Innovative Capillary Electrophoresis Techniques for Gene Therapy R&D at ProteinSimple
Learn how various capillary electrophoresis techniques can be easily implemented along the development path to support gene therapy development.
The Next Generation of AAV Characterization Tools by ProteinSimple
In this webinar, join Tony Bou Kheir, PhD, from the Cell and Gene Therapy Catapult in London, as he showcases the Cell and Gene Therapy Catapult’s adeno-associated viruses (AAV) analytical platform and advantages it offers to current industry standards.
Cell and Gene Therapy Virtual Symposium - Will Non-Viral Gene Delivery Be the Future of Genetic Ex Vivo Modification?
Bio-Techne looks forward to welcoming you to this exciting virtual symposium event to discuss the latest topics within the Cell & Gene Therapy community. This event aims to keep everyone connected, communicating and collaborating to advance the cell and gene therapy research and beyond from discovery to clinic.
Advances in Cell & Gene Therapy Analytics – How to Use Maurice to characterize AAVs and LNPs
Gene therapy holds promise for treating a wide range of diseases by precisely altering the genetic composition of cells. Join John Lougheny, director of VAR&D at Merck & Co. Inc. and Chris Heger from ProteinSimple as they demonstrate how the Maurice platform can be used to measure surface charge of an LNP-based mRNA vaccine, and how to assess purity, stability and concentration of AAVs.
LSCN-Bio-Techne: Organoid and Stem Cell Virtual Workshop
Bio-Techne is proud to partner with the London Stem Cell Network (LSCN) to present our first Stem Cell and Organoid Virtual Workshop. Watch on-demand now to learn more from leading experts on the advances in stem cells and organoids, including a panel discussion looking to the future of induced pluripotent stem cell (iPSC) therapies.
Organoid and 3-D cell culture are emerging as pivotal systems for understanding human organ development, modeling disease, screening for drug efficacy or toxicity, and investigating personalized medicine. The reagents and protocols needed to culture these advanced multi-cellular in vitro tissues vary by organ, species, and whether they are being generated from tissue or pluripotent stem cells. Watch on demand to find out direct from leading scientists how they are utilizing organoids within their research.
Tools to Optimize Neural and Cardiac Differentiation from iPSCs: Predicting Variability and Characterizing Differentiation Efficiency
Using iPSC-derived neurons and iPSC-derived cardiomyocytes as examples, this webinar discusses tools to help researchers manage iPSC variability, optimize cell differentiation, monitor and characterize differentiation efficiency, and translate their protocols towards clinical application.
Defining a Regulatory Path for iPSCs Based Cell Therapy
Induced pluripotent stem cells are a potential source for developing autologous cell therapies. Here we provide a streamlined regulatory (cell manufacturing and preclinical) path towards filing an Investigational New Drug (IND) application to conduct a phase I clinical trial using autologous iPSCs.
Allogeneic Cell Therapies – May 17-19, 2021
International Society for Cell and Gene Therapy – May 26-28, 2021
American Society of Clinical Oncology (ASCO) – June 4-8, 2021
CASSS Cell & Gene Therapy Products – June 7-10, 2021
Phacilitate Automation – June 21-25, 2021
International Society for Stem Cell Research – June 23-25, 2021
Cell and Gene Therapy Bioprocessing & Commercialization – September 20-23, 2021